Winton Group’s Anika Therapeutics ANIK Stock Holding History

Winton Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-73,029	Closed	-$2.11M	–	1441
2020 Q1	$2.11M	Sell	73,029 -18,592	-20%	-$752K	0.06%	556
2019 Q4	$4.75M	Buy	91,621 +54,015	+144%	+$3.14M	0.07%	487
2019 Q3	$2.06M	Buy	37,606 +29,429	+360%	+$1.51M	0.02%	561
2019 Q2	$332K	Buy	+8,177	New	+$298K	0.01%	851
2018 Q2	–	Sell	-8,066	Closed	-$401K	–	1006
2018 Q1	$401K	Buy	+8,066	New	+$456K	0.01%	868

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Winton Group's ANIK Position: Q2 2020 in Review

Winton Group sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 73,029 shares — an estimated $2.11M sold.

Winton Group first reported a position in ANIK in Q1 2018 and held it in 5 quarters. The position peaked at $4.75M in Q4 2019. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

Winton Group reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
Winton Group sold 73,029 Anika Therapeutics shares in Q2 2020, an estimated $2.11M.
Winton Group first reported a position in Anika Therapeutics in Q1 2018 and held it in 5 quarters.
Winton Group's Anika Therapeutics position peaked at $4.75M in Q4 2019.
158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Winton Group's 13F filing for Q2 2020, filed 5 Aug 2020.